The Effects of Topiroxostat, a Selective Xanthine Oxidoreductase Inhibitor, on Arterial Stiffness in Hyperuricemic Patients with Liver Dysfunction: A Sub-Analysis of the BEYOND-UA Study
暂无分享,去创建一个
K. Kario | I. Shimomura | S. Fukuda | H. Nishizawa | N. Maeda | S. Kita | S. Hoshide | Y. Fujishima | Y. Ono | Takashi Nakamura | Yusuke Kawachi | Seigo Akari | Shunbun Kita
[1] A. Doney,et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial , 2022, The Lancet.
[2] K. Kario,et al. Differential effect of a xanthine oxidase inhibitor on arterial stiffness and carotid atherosclerosis: a subanalysis of the PRIZE study , 2022, Hypertension Research.
[3] I. Shimomura,et al. Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease , 2022, Hypertension Research.
[4] I. Tatsuno,et al. Association of Plasma Xanthine Oxidoreductase with Arterial Stiffness in Type 2 Diabetes with Liver Dysfunction. , 2021, The American journal of the medical sciences.
[5] I. Shimomura,et al. Increased plasma XOR activity induced by NAFLD/NASH and its possible involvement in vascular neointimal proliferation , 2021, JCI insight.
[6] K. Kario,et al. Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia , 2021, Journal of clinical hypertension.
[7] I. Shimomura,et al. Plasma xanthine oxidoreductase activity in Japanese patients with type 2 diabetes across hospitalized treatment , 2020, Journal of diabetes investigation.
[8] M. Lanaspa,et al. Uric acid and hypertension , 2020, Hypertension Research.
[9] H. Tomiyama,et al. State of the Art Review: Brachial-Ankle PWV , 2020, Journal of atherosclerosis and thrombosis.
[10] Y. Moriwaki,et al. Japanese Society of Gout and Uric & Nucleic Acids 2019 Guidelines for Management of Hyperuricemia and Gout 3rd edition , 2020 .
[11] M. Honda,et al. Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice , 2020, Scientific Reports.
[12] M. Honda,et al. Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice , 2020, Scientific Reports.
[13] R. Townsend,et al. Large-Artery Stiffness in Health and Disease: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.
[14] I. Hisatome,et al. Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy , 2019, European heart journal.
[15] N. Ogawa,et al. The influence of albumin on the plasma xanthine oxidoreductase inhibitory activity of allopurinol, febuxostat and topiroxostat: Insight into extra-urate lowering effect , 2019, Integrative Molecular Medicine.
[16] E. Fukusaki,et al. Hypoxanthine Secretion from Human Adipose Tissue and its Increase in Hypoxia , 2018, Obesity.
[17] M. Oka,et al. A highly sensitive assay of human plasma xanthine oxidoreductase activity using stable isotope-labeled xanthine and LC/TQMS. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[18] Yingying Ding,et al. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis , 2016, Scientific Reports.
[19] Corrado Barbui,et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. , 2016, Journal of hepatology.
[20] M. Nagai,et al. Serum Uric Acid and Mortality Form Cardiovascular Disease: EPOCH-JAPAN Study. , 2016, Journal of atherosclerosis and thrombosis.
[21] Chao Lu,et al. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. , 2016, Journal of hepatology.
[22] E. Kelley. A new paradigm for XOR-catalyzed reactive species generation in the endothelium , 2015, Pharmacological reports : PR.
[23] T. Asano,et al. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic 1 steatohepatitis in a rodent model 2 3 1 , 2015 .
[24] P. Liu,et al. The Effects of Allopurinol on the Carotid Intima-media Thickness in Patients with Type 2 Diabetes and Asymptomatic Hyperuricemia: A Three-year Randomized Parallel-controlled Study. , 2015, Internal medicine.
[25] J. Ampuero,et al. Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis. , 2015, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.
[26] A. Hirayama,et al. A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[27] T. Saibara,et al. Upper limit of normal serum alanine aminotransferase levels in Japanese subjects , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.
[28] L. Polito,et al. Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme. , 2014, Biochimica et biophysica acta.
[29] H. Khan,et al. Liver enzymes and risk of cardiovascular disease in the general population: a meta-analysis of prospective cohort studies. , 2014, Atherosclerosis.
[30] Ping Zhu,et al. Serum Uric Acid Is Associated with Incident Chronic Kidney Disease in Middle-Aged Populations: A Meta-Analysis of 15 Cohort Studies , 2014, PloS one.
[31] P. Higgins,et al. Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: a randomised controlled trial , 2014, Heart.
[32] X. Qin,et al. Complex Association between Alanine Aminotransferase Activity and Mortality in General Population: A Systematic Review and Meta-Analysis of Prospective Studies , 2014, PloS one.
[33] K. Shimamoto. The Japanese Society of Hypertension Guidelines for the Management of Hypertension 2014 (JSH2014) , 2014 .
[34] Yutaka Imai,et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014) , 2014, Hypertension Research.
[35] M. Emdin,et al. Gamma-glutamyltransferase activity in human atherosclerotic plaques--biochemical similarities with the circulating enzyme. , 2009, Atherosclerosis.
[36] S. Marklund,et al. Binding of Xanthine Oxidase to Vascular Endothelium , 1999, The Journal of Biological Chemistry.
[37] S. Yamashita,et al. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. , 1998, Metabolism: clinical and experimental.
[38] K. Hirano,et al. Binding of human xanthine oxidase to sulphated glycosaminoglycans on the endothelial-cell surface. , 1993, The Biochemical journal.